Personalis’ Medicare coverage wins for NeXT Personal MRD

Medicare’s expanding coverage of Personalis’ NeXT Personal® MRD assay is another major signal that ultra‑sensitive, tumor‑informed ctDNA testing is becoming a core component of cancer surveillance. NeXT Personal now has Medicare coverage for: 🔹 Stage II–III breast cancer — recurrence surveillance across all major subtypes, with coverage extending up to six years post‑treatment. 🔹 Stage I–III NSCLC — supported by landmark evidence from TRACERx showing ctDNA can detect recurrence well before imaging. These decisions reflect growing payer confidence in Molecular Residual Disease testing and its clinical utility—particularly its ability to detect recurrence months to years earlier than standard monitoring. For patients and clinicians, this means earlier opportunities for intervention. For the diagnostics industry, it’s a clear validation of where oncology testing is headed. As MRD adoption accelerates, the competitive landscape is shifting quickly across tumor‑informed, tumor‑naïve, and whole‑genome approaches. Understanding how each platform differentiates—analytically, clinically, and commercially—is becoming essential for strategy, Business Development, and investment decisions. That’s why we built the GRN IVD Consulting In‑vitro Cancer Testing Market Report: ✔ Comprehensive MRD & MCED competitive intelligence ✔ Clinical‑algorithm mapping across major tumor types ✔ Reimbursement and regulatory signal tracking ✔ Platform‑level performance comparisons ✔ Strategic recommendations for positioning and partnerships If you’re navigating the future of cancer diagnostics, this report gives you the clarity to move with confidence. Login for a copy of the report.